2cureX (2CUREX) H1 2026 earnings summary

Executive summary

• Strengthened financial position through an oversubscribed directed share issue, raising approximately SEK 7.51 million before costs.

• Advanced commercial development and prepared for decentralised IndiTreatⓇ hospital installations in H2 2026.

• Entered a strategic collaboration with StoreMyTumor to enhance tumour logistics and patient coordination.

• Evaluated a potential combination of 2cureX AB and 2cureX A/S to unify technology, people, and commercialisation efforts.

• Following Nasdaq Stockholm's delisting decision, preparations for relisting on an alternative marketplace are underway.

Financial highlights

• Oversubscribed directed share issue resulted in 6,541,736 new shares, increasing total shares to 31,644,652.

• Financial figures for H1 2026 were deferred due to the transition to a new trading venue; figures will be provided as the relisting process advances.

Outlook and guidance

• Focus on preparing IndiTreatⓇ for initial hospital installations and converting commercial discussions into contracts.

• Continued disciplined capital allocation and securing financing for commercial execution.

• Ongoing preparations for relisting on an alternative marketplace.